Desirable drug–drug interactions or when a matter of concern becomes a renewed therapeutic strategy
- 1 February 2021
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 26 (2) , 315-328
Abstract
No abstract availableKeywords
This publication has 97 references indexed in Scilit:
- Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivoBMC Cancer, 2013
- The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial designBritish Journal of Clinical Pharmacology, 2013
- Shifting from the single to the multitarget paradigm in drug discoveryDrug Discovery Today, 2013
- Avibactam is a covalent, reversible, non–β-lactam β-lactamase inhibitorProceedings of the National Academy of Sciences, 2012
- Efflux pump-mediated resistance in chemotherapyAnnals of Medical and Health Sciences Research, 2012
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR InhibitorsScience Translational Medicine, 2011
- Ethionamide Boosters: Synthesis, Biological Activity, and Structure−Activity Relationships of a Series of 1,2,4-Oxadiazole EthR InhibitorsJournal of Medicinal Chemistry, 2011
- Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivoBritish Journal of Cancer, 2009
- Mechanism of thioamide drug action against tuberculosis and leprosyJournal of Experimental Medicine, 2007
- Levamisole and Fluorouracil for Adjuvant Therapy of Resected Colon CarcinomaNew England Journal of Medicine, 1990